Search

Your search keyword '"Naito, Renato"' showing total 158 results
Start Over Author "Naito, Renato"
158 results on '"Naito, Renato"'

4. Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer.

Author

Iwamoto, Hiroaki, Hori, Tomohiro, Nakagawa, Ryunosuke, Kano, Hiroshi, Makino, Tomoyuki, Naito, Renato, Yaegashi, Hiroshi, Kawaguchi, Shohei, Nohara, Takahiro, Shigehara, Kazuyoshi, Izumi, Kouji, and Mizokami, Atsushi

Subjects
THERAPEUTIC use of antineoplastic agents, CASTRATION-resistant prostate cancer, ANTIANDROGENS, PATIENT selection, RISK assessment, ACADEMIC medical centers, PROSTATE-specific antigen, CANCER patients, MULTIVARIATE analysis, TUMOR grading, RETROSPECTIVE studies, DESCRIPTIVE statistics, METASTASIS, KAPLAN-Meier estimator, MEDICAL records, ACQUISITION of data, STATISTICS, DRUG efficacy, CONFIDENCE intervals, ANDROGEN receptors, OVERALL survival
Abstract

Simple Summary: Upfront novel androgen receptor signaling inhibitors (ARSIs) are the first-line treatment for metastatic castration-sensitive prostate cancer (mCSPC). However, there are a certain number of cases in which androgen deprivation therapy (ADT) is more effective in patients of Asian descent. If we can identify patients who show a marked response to ADT within 12 weeks after ADT, which is the inclusion criterion for upfront ARSI clinical trials, it would be valuable from an economic standpoint. A total of 218 patients who received ADT treatment at Kanazawa University Hospital between 2000 and 2020 were included in this study. Multivariate analysis revealed that a decrease in PSA levels of <95% at 12 weeks after ADT initiation was a predictor of short time to castration resistance (TTCR) in low-risk patients. We propose a new treatment strategy, in which patients with low-risk mCSPC are treated with ADT and switched to ARSIs, based on the rate of PSA reduction at 12 weeks. Background: The treatment strategy for metastatic castration-sensitive prostate cancer (mCSPC) has changed significantly in recent years. Based on various guidelines, an upfront androgen receptor signaling inhibitor (ARSI) is the first choice, but in patients of Asian descent, including Japanese patients, there are a certain number of cases in which androgen deprivation therapy (ADT) and CAB are more effective. If patients can be identified who show a marked response to ADT within 12 weeks after the initiation of ADT, which is the inclusion criterion for ARSI clinical trials targeting mCSPC, it would be valuable from an economic standpoint. Methods: A total of 218 patients with pure prostate adenocarcinoma and treated with ADT at the Kanazawa University Hospital between January 2000 and December 2020 were included in this study. As a risk classification for mCSPC, in addition to the LATITUDE and CHAARTED criteria, we used the castration-sensitive prostate cancer classification proposed by Kanazawa University (Canazawa), developed by the Department of Urology of Kanazawa University. The Canazawa classification was based on three factors: Gleason pattern 5, bone scan index (BSI) ≥ 1.5, and lactate dehydrogenase (LDH) ≥ 300 IU/L. It defined patients with one factor or less as low-risk and patients with two or three factors as high-risk. The overall survival (OS) and time to castration resistance (TTCR) were estimated retrospectively using the Kaplan–Meier method, and factors associated with TTCR were identified using univariate and multivariate analyses. Results: The median follow-up period was 40.4 months, the median OS period was 85.2 months, and the median TTCR period was 16.4 months. The Canazawa risk classification provided the clearest distinction between the OS and TTCR in mCSPC patients. Multivariate analysis revealed a decrease in PSA levels of <95% at 12 weeks after ADT initiation and was a predictor of short TTCR in low-risk, low-volume patients across all risk classifications. Conclusion: The Canazawa classification differentiated the prognosis of mCSPC patients more clearly. A PSA reduction rate of <95% at 12 w after starting ADT in low-risk, low-volume patients of all risk classifications was significantly shorter than the TTCR. We propose a new treatment strategy, in which patients with low-risk mCSPC are treated with ADT and switched to ARSIs based on the rate of PSA reduction at 12 w. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Comprehensive analysis of perioperative hypotension in photodynamic diagnosis‐assisted transurethral resection of bladder tumor with 5‐aminolevulinic acid.

Author

Nohara, Takahiro, Takimoto, Atsuya, Shinzawa, Rei, Kurauchi, Daimon, Toriumi, Ren, Nakagawa, Ryunosuke, Aoyama, Shuhei, Kamijima, Taiki, Kano, Hiroshi, Naito, Renato, Kadomoto, Suguru, Iwamoto, Hiroaki, Yaegashi, Hiroshi, Kawaguchi, Shohei, Shigehara, Kazuyoshi, Izumi, Kouji, and Mizokami, Atsushi

Subjects
TRANSURETHRAL resection of bladder, ORAL drug administration, SPINAL anesthesia, KIDNEY physiology, GENERAL anesthesia, BLADDER cancer
Abstract

Objective: Intraoperative hypotension remains a serious adverse event of photodynamic diagnosis‐assisted transurethral resection of bladder tumor with oral administration of 5‐aminolevulinic acid. We conducted a re‐analysis of perioperative hypotension in photodynamic diagnosis‐assisted transurethral resection of the bladder tumor with oral 5‐aminolevulinic acid to ascertain its safety. Methods: A total of 407 cases who underwent transurethral resection of bladder tumors in our institution were reviewed (274 cases for the PDD group with photodynamic diagnosis and 133 for the white light (WL) group without). A classification of hypotension severity was devised to identify risk factors for clinically troublesome hypotension. The distribution of hypotension severity in each of the PDD and WL groups was compared. Additionally, the patient background and perioperative data by hypotension severity were compared only in the PDD group. Results: More patients with moderate and severe hypotension were noted in the PDD group. The renal function was lower with increasing hypotension severity in the PDD group. More patients on general anesthesia were included in the mild and moderate hypotension group, whereas more patients on spinal anesthesia were included in the severe hypotension group. Furthermore, the frequency of side effects other than hypotension tended to increase with hypotension severity. Conclusions: Renal function impairment and the other adverse effects of 5‐aminolevulinic acid may be risk factors for severe hypotension. Mild or moderate hypotension may be caused by general anesthesia and severe hypotension may be caused by spinal anesthesia. To elucidate specific risk factors, further case–control studies are warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?

Author

Nakagawa, Ryunosuke, Izumi, Kouji, Toriumi, Ren, Aoyama, Shuhei, Kamijima, Taiki, Makino, Tomoyuki, Naito, Renato, Iwamoto, Hiroaki, Yaegashi, Hiroshi, Kawaguchi, Shohei, Shigehara, Kazuyoshi, Nohara, Takahiro, and Mizokami, Atsushi

Subjects
BLADDER cancer, CONSERVATIVE treatment, ILEAL conduit surgery, CYSTECTOMY, PROGNOSIS, BLADDER, LENGTH of stay in hospitals
Abstract

Purpose: To compare the prognosis and quality of life between radical cystectomy and bladder conservative treatment for muscle invasive bladder cancer in the real world. Materials and Methods: Patients treated for muscle invasive bladder cancer without metastases were retrospectively evaluated for overall survival, progression‐free survival, and rehospitalization. Results: Of the 141 patients, 62 underwent bladder conservative treatment and 79 underwent radical cystectomy. Patients who underwent radical cystectomy had significantly better progression‐free survival (HR: 1.83, 95% CI: 1.12–3.00; p < 0.01) and overall survival (HR: 1.82, 95% CI: 0.99–3.34; p = 0.03) than those who underwent conservative treatment. However, there was no significant difference in prognosis between patients who refused to undergo radical cystectomy and those who underwent. In addition, rehospitalization rates for complications and additional treatment were significantly higher in patients who received conservative treatment (69.3% vs. 34.2%; p < 0.01), and the length of hospital stay was also prolonged compared to patients who received radical cystectomy (26 vs. 9 days; p = 0.03). Conclusions: Overall, conservative treatment had a significantly poorer prognosis than radical cystectomy, but there was no significant difference in prognosis when comparing patients who refused radical cystectomy and received conservative treatment with those who received radical cystectomy. However, hospitalization rates and length of stay were significantly worse for patients who chose conservative treatment, which may lead to a decline in quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. A seed link connector protruding into the bladder formed a bladder stone

Author

Aoyama, Shuhei, primary, Izumi, Kouji, additional, Makino, Tomoyuki, additional, Naito, Renato, additional, Kadomoto, Suguru, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Kawaguchi, Shohei, additional, Shigehara, Kazuyoshi, additional, Nohara, Takahiro, additional, and Mizokami, Atsushi, additional

Published
2024
Full Text
View/download PDF

9. Urinary tract symptoms that should be improved to enhance post-operative urinary quality of life in patients treated with low-dose-rate brachytherapy for prostate cancer: An importance–performance analysis

Author

Sakurai, Takayuki, primary, Takamatsu, Shigeyuki, additional, Shibata, Satoshi, additional, Minamikawa, Risako, additional, Yamazaki, Masahiro, additional, Okubo, Akihito, additional, Nagaoka, Risa, additional, Makino, Tomoyuki, additional, Naito, Renato, additional, Yaegashi, Hiroshi, additional, Mizokami, Atsushi, additional, and Kobayashi, Satoshi, additional

Published
2024
Full Text
View/download PDF

11. Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells

Author

Makino, Tomoyuki, Izumi, Kouji, Hiratsuka, Kaoru, Kano, Hiroshi, Shimada, Takashi, Nakano, Taito, Kadomoto, Suguru, Naito, Renato, Iwamoto, Hiroaki, Yaegashi, Hiroshi, Shigehara, Kazuyoshi, Kadono, Yoshifumi, Nakata, Hiroki, Saito, Yohei, Nakagawa-Goto, Kyoko, Sakai, Norihiko, Iwata, Yasunori, Wada, Takashi, and Mizokami, Atsushi

Published
2021
Full Text
View/download PDF

12. Role of Positive Biopsy Core Ratio in Prostate Cancer Patients

Author

KANO, HIROSHI, primary, IZUMI, KOUJI, additional, NAKAGAWA, RYUNOSUKE, additional, TORIUMI, REN, additional, AOYAMA, SHUHEI, additional, KAMIJIMA, TAIKI, additional, SHIMADA, TAKAFUMI, additional, NAITO, RENATO, additional, KADOMOTO, SUGURU, additional, IWAMOTO, HIROAKI, additional, YAEGASHI, HIROSHI, additional, KAWAGUCHI, SHOHEI, additional, NOHARA, TAKAHIRO, additional, SHIGEHARA, KAZUYOSHI, additional, KADONO, YOSHIFUMI, additional, and MIZOKAMI, ATSUSHI, additional

Published
2023
Full Text
View/download PDF

13. Bone Turnover Markers, n-Terminal Propeptide of Type I Procollagen and Tartrate-Resistant Acid Phosphatase Type 5b, for Predicting Castration Resistance in Prostate Cancer.

Author

Kano, Hiroshi, Izumi, Kouji, Nakagawa, Ryunosuke, Toriumi, Ren, Aoyama, Shuhei, Kamijima, Taiki, Makino, Tomoyuki, Naito, Renato, Iwamoto, Hiroaki, Yaegashi, Hiroshi, Kawaguchi, Shohei, Shigehara, Kazuyoshi, Nohara, Takahiro, and Mizokami, Atsushi

Subjects
ACID phosphatase, BONE remodeling, PROSTATE cancer, CASTRATION-resistant prostate cancer, COLLAGEN
Abstract

Bone is a common site of prostate cancer metastasis. Bone turnover markers n-terminal propeptide of type I procollagen (P1NP) and tartrate-resistant acid phosphatase type 5b (TRACP-5b) are highly sensitive to bone remodeling activity. However, their prognostic significance as markers of prostate cancer is unknown. This study retrospectively examined the usefulness of P1NP and TRACP-5b as prognostic biomarkers. Castration-resistant prostate cancer recurrence-free survival (CFS) was estimated using the Kaplan–Meier method. A predictive model for CFS was constructed using multivariate analysis. This study enrolled 255 patients diagnosed with prostate cancer at Kanazawa University Hospital. The median follow-up was 115.1 months. Patients with both high serum P1NP and TRACP-5b levels, defined as having a poor bone turnover category (BTC), had significantly shorter CFS. Multivariate analysis identified Gleason score, metastasis, and BTC poor as predictors for castration resistance in prostate cancer. Using these three factors, a prognostic model was established, categorizing patients into low-risk (no or one factor) and high-risk (two or three factors) groups. In the low-risk group, the median CFS was not reached, contrasting with 19.1 months in the high-risk group (hazard ratio, 32.23, p < 0.001). Combining P1NP and TRACP-5b may better predict castration resistance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells

Author

SHIMADA, TAKAFUMI, primary, NAITO, RENATO, additional, TORIUMI, REN, additional, NAKAGAWA, RYUNOSUKE, additional, AOYAMA, SHUHEI, additional, KAMIJIMA, TAIKI, additional, KANO, HIROSHI, additional, KADOMOTO, SUGURU, additional, IWAMOTO, HIROAKI, additional, YAEGASHI, HIROSHI, additional, IZUMI, KOUJI, additional, KADONO, YOSHIFUMI, additional, NAKATA, HIROKI, additional, SAITO, YOHEI, additional, NAKAGAWA-GOTO, KYOKO, additional, and MIZOKAMI, ATSUSHI, additional

Published
2023
Full Text
View/download PDF

17. Comparison of postoperative urinary continence and incontinence types between conventional and Retzius‐sparing robot‐assisted radical prostatectomy

Author

Kadono, Yoshifumi, primary, Nohara, Takahiro, additional, Kawaguchi, Shohei, additional, Makino, Tomoyuki, additional, Naito, Renato, additional, Kadomoto, Suguru, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Shigehara, Kazuyoshi, additional, Izumi, Kouji, additional, and Mizokami, Atsushi, additional

Published
2023
Full Text
View/download PDF

19. Intravesical Bacille Calmette–Guerin Therapy with Photodynamic Diagnosis Transurethral Resection of Bladder Tumor Improves Recurrence-Free Survival

Author

Nakagawa, Ryunosuke, primary, Nohara, Takahiro, additional, Naito, Renato, additional, Kadomoto, Suguru, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Kawaguchi, Shohei, additional, Shigehara, Kazuyoshi, additional, Izumi, Kouji, additional, Kadono, Yoshifumi, additional, and Mizokami, Atsushi, additional

Published
2023
Full Text
View/download PDF

20. Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20 – CCR6 axis

Author

Kano, Hiroshi, primary, Izumi, Kouji, additional, Hiratsuka, Kaoru, additional, Toriumi, Ren, additional, Nakagawa, Ryunosuke, additional, Aoyama, Shuhei, additional, Kamijima, Taiki, additional, Shimada, Takafumi, additional, Naito, Renato, additional, Kadomoto, Suguru, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Kawaguchi, Shohei, additional, Nohara, Takahiro, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, Saito, Yohei, additional, Nakagawa‐Goto, Kyoko, additional, Yoshioka, Kazuaki, additional, Nakata, Hiroki, additional, Lin, Wen‐Jye, additional, and Mizokami, Atsushi, additional

Published
2022
Full Text
View/download PDF

22. Comparison of Clinical Outcomes between Robot-Assisted Partial Nephrectomy and Cryoablation in Elderly Patients with Renal Cancer

Author

Kawaguchi, Shohei, primary, Izumi, Kouji, additional, Naito, Renato, additional, Kadomoto, Suguru, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Nohara, Takahiro, additional, Shigehara, Kazuyoshi, additional, Yoshida, Kotaro, additional, Kadono, Yoshifumi, additional, and Mizokami, Atsushi, additional

Published
2022
Full Text
View/download PDF

23. Does Bladder Cancer with Inchworm Sign Indicate Better Prognosis after TURBT?

Author

Nakagawa, Ryunosuke, primary, Izumi, Kouji, additional, Naito, Renato, additional, Kadomoto, Suguru, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Kawaguchi, Shohei, additional, Nohara, Takahiro, additional, Shigehara, Kazuyoshi, additional, Yoshida, Kotaro, additional, Kadono, Yoshifumi, additional, and Mizokami, Atsushi, additional

Published
2022
Full Text
View/download PDF

24. Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men

Author

Nakagawa, Ryunosuke, primary, Iwamoto, Hiroaki, additional, Makino, Tomoyuki, additional, Naito, Renato, additional, Kadomoto, Suguru, additional, Akatani, Norihito, additional, Yaegashi, Hiroshi, additional, Kawaguchi, Shohei, additional, Nohara, Takahiro, additional, Shigehara, Kazuyoshi, additional, Izumi, Kouji, additional, Kadono, Yoshifumi, additional, Takamatsu, Atsushi, additional, Yoshida, Kotaro, additional, and Mizokami, Atsushi, additional

Published
2022
Full Text
View/download PDF

25. Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer

Author

Iwamoto, Hiroaki, primary, Izumi, Kouji, additional, Nakagawa, Ryunosuke, additional, Toriumi, Ren, additional, Aoyama, Shuhei, additional, Kamijima, Taiki, additional, Shimada, Takafumi, additional, Kano, Hiroshi, additional, Makino, Tomoyuki, additional, Naito, Renato, additional, Kadomoto, Suguru, additional, Yaegashi, Hiroshi, additional, Kawaguchi, Shohei, additional, Nohara, Takahiro, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, and Mizokami, Atsushi, additional

Published
2022
Full Text
View/download PDF

26. Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20–CCR6 axis.

Author

Kano, Hiroshi, Izumi, Kouji, Hiratsuka, Kaoru, Toriumi, Ren, Nakagawa, Ryunosuke, Aoyama, Shuhei, Kamijima, Taiki, Shimada, Takafumi, Naito, Renato, Kadomoto, Suguru, Iwamoto, Hiroaki, Yaegashi, Hiroshi, Kawaguchi, Shohei, Nohara, Takahiro, Shigehara, Kazuyoshi, Kadono, Yoshifumi, Saito, Yohei, Nakagawa‐Goto, Kyoko, Yoshioka, Kazuaki, and Nakata, Hiroki

Abstract

The suppression of androgen receptor (AR) expression exacerbates the migration potential of prostate cancer. This study identified a previously unrecognized regulation of the AR‐controlled pathway that promotes migration potential in prostate cancer cells. Prostate cancer cells that pass through a transwell membrane (mig cells) have a higher migration potential with a decreased AR expression than parental cells. In this study, we aimed to elucidate the mechanism of migration enhancement associated with the suppression of AR signaling. Expression of C–C motif ligand 20 (CCL20) is upregulated in mig cells, unlike in the parental cells. Knockdown of AR with small interfering RNA (siAR) in LNCaP and C4‐2B cells increased CCL20 secretion and enhanced the migration of cancer cells. Mig cells, CCL20‐treated cells, and siAR cells promoted cell migration with an enhancement of AKT phosphorylation and Snail expression, while the addition of a C–C chemokine receptor 6 (CCR6, the specific receptor of CCL20) inhibitor, anti‐CCL20 antibody, and AKT inhibitor suppressed the activation of AKT and Snail. With 59 samples of prostate cancer tissue, CCL20 secretion was profuse in metastatic cases despite low AR expression levels. Snail expression was associated with the expression of CCL20 and CCR6. A xenograft study showed that the anti‐CCL20 antibody significantly inhibited Snail expression, thereby suggesting a new therapeutic approach for castration‐resistant prostate cancer with the inhibition of the axis between CCL20 and CCR6. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. A new flavonoid derivative exerts antitumor effects against androgen‐sensitive to cabazitaxel‐resistant prostate cancer cells

Author

Naito, Renato, primary, Kano, Hiroshi, additional, Shimada, Takashi, additional, Makino, Tomoyuki, additional, Kadomoto, Suguru, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Izumi, Kouji, additional, Kadono, Yoshifumi, additional, Nakata, Hiroki, additional, Saito, Yohei, additional, Goto, Masuo, additional, Nakagawa‐Goto, Kyoko, additional, and Mizokami, Atsushi, additional

Published
2021
Full Text
View/download PDF

32. Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer

Author

IWAMOTO, HIROAKI, primary, KANO, HIROSHI, additional, SHIMADA, TAKAFUMI, additional, NAITO, RENATO, additional, MAKINO, TOMOYUKI, additional, KADAMOTO, SUGURU, additional, YAEGASHI, HIROSHI, additional, SHIGEHARA, KAZUYOSHI, additional, IZUMI, KOUJI, additional, KADONOA, YOSHIFUMI, additional, and MIZOKAMI, ATSUSHI, additional

Published
2021
Full Text
View/download PDF

33. Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy

Author

IWAMOTO, HIROAKI, primary, KANO, HIROSHI, additional, SHIMADA, TAKAFUMI, additional, NAITO, RENATO, additional, MAKINO, TOMOYUKI, additional, KADOMOTO, SUGURU, additional, YAEGASHI, HIROSHI, additional, SHIGEHARA, KAZUYOSHI, additional, IZUMI, KOUJI, additional, KADONO, YOSHIFUMI, additional, and MIZOKAMI, ATSUSHI, additional

Published
2021
Full Text
View/download PDF

34. Androgen receptor signaling‐targeted therapy and taxane chemotherapy induce visceral metastasis in castration‐resistant prostate cancer

Author

Iwamoto, Hiroaki, primary, Izumi, Kouji, additional, Shimada, Takashi, additional, Kano, Hiroshi, additional, Kadomoto, Suguru, additional, Makino, Tomoyuki, additional, Naito, Renato, additional, Yaegashi, Hiroshi, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, and Mizokami, Atsushi, additional

Published
2020
Full Text
View/download PDF

37. MP18-06 TUMOR-ASSOCIATED MACROPHAGES INDUCE MIGRATION OF RENAL CELL CARCINOMA CELLS VIA ACTIVATION OF THE CCL20-CCR6 AXIS

Author

Kadomoto*, Suguru, primary, Izumi, Kouji, additional, Hiratsuka, Kaoru, additional, Nakano, Taito, additional, Naito, Renato, additional, Makino, Tomoyuki, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, Nakata, Hiroki, additional, and Mizokami, Atsushi, additional

Published
2020
Full Text
View/download PDF

39. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis

Author

Kadomoto, Suguru, primary, Izumi, Kouji, additional, Hiratsuka, Kaoru, additional, Nakano, Taito, additional, Naito, Renato, additional, Makino, Tomoyuki, additional, Iwamoto, Hiroaki, additional, Yaegashi, Hiroshi, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, Nakata, Hiroki, additional, Saito, Yohei, additional, Nakagawa-Goto, Kyoko, additional, and Mizokami, Atsushi, additional

Published
2019
Full Text
View/download PDF

45. Evaluating urinary incontinence before and after radical prostatectomy using the international consultation on incontinence questionnaire‐short form

Author

Machioka, Kazuaki, primary, Kadono, Yoshifumi, additional, Naito, Renato, additional, Nakashima, Kazufumi, additional, Iijima, Masashi, additional, Kawaguchi, Shohei, additional, Shigehara, Kazuyoshi, additional, Nohara, Takahiro, additional, Izumi, Kouji, additional, and Mizokami, Atsushi, additional

Published
2018
Full Text
View/download PDF

46. Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells

Author

Iwamoto, Hiroaki, primary, Izumi, Kouji, additional, Natsagdorj, Ariunbold, additional, Naito, Renato, additional, Makino, Tomoyuki, additional, Kadomoto, Suguru, additional, Hiratsuka, Kaoru, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, Narimoto, Kazutaka, additional, Saito, Yohei, additional, Nakagawa‐Goto, Kyoko, additional, and Mizokami, Atsushi, additional

Published
2018
Full Text
View/download PDF

47. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells

Author

Natsagdorj, Ariunbold, primary, Izumi, Kouji, additional, Hiratsuka, Kaoru, additional, Machioka, Kazuaki, additional, Iwamoto, Hiroaki, additional, Naito, Renato, additional, Makino, Tomoyuki, additional, Kadomoto, Suguru, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, Lin, Wen‐Jye, additional, Maolake, Aerken, additional, and Mizokami, Atsushi, additional

Published
2018
Full Text
View/download PDF

48. A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age.

Author

Iwamoto, Hiroaki, Izumi, Kouji, Kadomoto, Suguru, Makino, Tomoyuki, Naito, Renato, Yaegashi, Hiroshi, Shigehara, Kazuyoshi, Kadono, Yoshifumi, and Mizokami, Atsushi

Abstract

A standard modality for prostate cancer detection in men 75 years and older has not been established. A simple screening method for elderly patients is needed to avoid unnecessary biopsies and to effectively diagnose prostate cancer. A retrospective study was conducted on elderly patients who had prostate biopsy at Kanazawa University Hospital (Kanazawa, Japan) between 2000 and 2017. Of the 2251 patients who underwent prostate biopsy, 254 had clinically significant prostate cancer (CSPC) with a Gleason score (GS) of ≥ 7 and 273 had a GS of <7 or no malignancy. In this study, patients aged 75 years or older were classified as elderly patients. GS ≥ 7 was characterized by a prostate-specific antigen (PSA) of the maximum area under the curve of 12 ng ml−1 with a sensitivity of 76.2% and a specificity of 73.2%. For PSA levels between 4 ng ml−1 and 12 ng ml−1, based on the maximum area under the curve, patients with three or four of the following factors may present a GS of ≥ 7: percent free PSA >24, PSA density ≥ 0.24 ng ml−2, positive findings on digital rectal examination, and transrectal with 90.0% sensitivity and 67.4% specificity. In this study, we found that raising the PSA cutoff to 12 ng ml−1 for CSPC in elderly individuals can significantly reduce unnecessary prostate biopsies. Furthermore, CSPC could be efficiently discovered by combining the four supplementary markers in patients with a PSA level of 4–12 ng ml−1. By performing this screening for elderly men over 75 years of age, unnecessary biopsies may be reduced and CSPC may be detected efficiently. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Tumor necrosis factor‐α induces prostate cancer cell migration in lymphatic metastasis through CCR 7 upregulation

Author

Maolake, Aerken, primary, Izumi, Kouji, additional, Natsagdorj, Ariunbold, additional, Iwamoto, Hiroaki, additional, Kadomoto, Suguru, additional, Makino, Tomoyuki, additional, Naito, Renato, additional, Shigehara, Kazuyoshi, additional, Kadono, Yoshifumi, additional, Hiratsuka, Kaoru, additional, Wufuer, Guzailinuer, additional, Nastiuk, Kent L., additional, and Mizokami, Atsushi, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results